F S&P 500
5,241.50 +2.50 (+0.05%) F Dow Jones
39,572.00 +36.00 (+0.09%) F Nasdaq
18,218.75 +4.25 (+0.02%) E-mini Russell 2000 Index Futur
2,085.40 +1.30 (+0.06%) Petróleo
79.71 +0.45 (+0.57%) Oro
2,356.50 +16.20 (+0.69%)
Statera Biopharma, Inc. (STAB)
Statera Biopharma, Inc.
4333 Corbett Drive
Suite 1082
Fort Collins, CO 80525
United States
888 613 8802
https://www.staterabiopharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 46
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael Kevin Handley | CEO, President & Chairman of the Board | 2.87M | N/D | 1972 |
| Mr. Christopher Zosh | Executive VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer | N/D | N/D | 1976 |
| Dr. Robert W. Buckheit Jr., Ph.D. | Chief Technology Officer | N/D | N/D | 1960 |
Descripción
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.
Gestión corporativa
La calificación ISS Governance QuickScore de Statera Biopharma, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
